Table 2 Reported adverse events from glofitamab therapy
Author | Study | Regimen | Grade ≥ 3 AEs | Grade 1–2 CRS | Grade 3–5 CRS |
|---|---|---|---|---|---|
Max S. Topp | Phase Ib | Glofitamab combined with R-CHOP | 71.4% | 10.7% | 0 |
Martin Hutchings | Phase I | RO7227166 combined with glofitamab | 57.2% | 54.3% | 0 |
Anna Dodero | Retrospective | Glofitamab | – | – | – |
Martin Hutchings | Retrospective | Glofitamab | – | – | – |
Burhan Ferhanoglu | Retrospective (compassionate use) | Glofitamab | 23% | 28.6% | 8.6% |